key: cord-0930742-45h3yi5k
authors: Benotmane, Ilies; Gautier ‐Vargas, Gabriela; Gallais, Floriane; Gantner, Pierre; Cognard, Noëlle; Olagne, Jérôme; Velay, Aurélie; Heibel, Françoise; Braun‐Parvez, Laura; Martzloff, Jonas; Perrin, Peggy; Moulin, Bruno; Fafi‐Kremer, Samira; Caillard, Sophie
title: Strong antibody response after a first dose of a SARS‐CoV‐2 mRNA‐based vaccine in kidney transplant recipients with a previous history of COVID‐19
date: 2021-07-23
journal: Am J Transplant
DOI: 10.1111/ajt.16764
sha: d1d59ffb4c91e96f6f86c27d8be7983fa53dc6a9
doc_id: 930742
cord_uid: 45h3yi5k

A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).1,2 While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,3-5 the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.

To the Editor:

A recent study demonstrated that a single dose of a severe acute Titers >50 arbitrary units (AUs)/mL were considered positive (detection range: 6.8-80000 AUs/mL). This assay has been reported to correlate with in vitro neutralization of SARS-CoV-2. 1 The study protocol was approved by the local Ethics Committee (approval DC-2013-1990), and written informed consent was obtained. 10768−78339 AUs/mL, p < 0.0001; Figure 1A ). After vaccination, KTRs who required hospitalization (n = 19) had a higher antibody titer compared with those who were managed at home (n = 22; median antibody titer: 49531 AUs/mL vs. 14334 AUs/mL, respectively, p = 0.04, Figure 1B) . However, no significant differences in prevaccination antibody titers were observed between the two groups (median antibody titer: 842 vs. 958 AUs/mL, respectively, p = 0.7). Figure 1C ) from that observed in KTRs.

Despite their immunosuppression burden, KTRs with previous exposure to SARS-CoV-2 showed a marked increase in antibody titers even after a single-dose vaccine. Notably, the postvaccination antibody titers observed in these immunosuppressed patients were similar to those of immunocompetent subjects. A preexisting B cell memory in recovered individuals is likely to play a key role in this phenomenon 2 -which suggests that the immune response of KTRs to SARS-CoV-2 is similar to that observed in immunocompetent individuals. This response is strikingly different from that described for SARS-CoV-2-naïve KTRs who received SARS-CoV-2 mRNA-based vaccines. [3] [4] [5] An "antigen dose" phenomenon may account for these discrepancies.

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Dr Caillard reports personal fees and nonfinancial support from Novartis, nonfinancial support from Sanofi, and nonfinancial support from Astellas, unrelated to the current study. The other authors have no conflict of interest to disclose.

Data supporting the findings from this study are available from the corresponding author upon reasonable request.

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients